Shandong Weigao Group Medical Polymer Company Limited (01066) disclosed a repurchase of 14,000 H shares on 24 October 2025 on The Stock Exchange of Hong Kong at a price of HKD 5.63 per share, for a total consideration of HKD 78,820. Following the transaction, the number of treasury shares increased from 22,268,800 to 22,282,800, while the issued shares excluding treasury shares declined to 4,500,049,524. The total number of issued shares remained 4,522,332,324.

According to the announcement, the repurchase was made under a mandate dated 27 May 2025, which authorized up to 451,560,392 shares for repurchase. The company has repurchased a cumulative total of 15,634,400 shares under this mandate, representing approximately 3.4623% of its issued shares (excluding treasury shares) at the time the mandate was granted. A 30-day moratorium period on new share issuance or sale/transfer of treasury shares is in effect until 23 November 2025.